UNSPSC 51182020: Bolandiol

This classification denotes an anabolic steroid with the molecular formula C18H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49SD6G16U5, chemically known as 3.beta.,17.beta.-dihydroxyestr-4-ene but generally known as bolandiol, which bears US NIH Compound Identifier 70691434. European Medicines Agency schedules bolandiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05866MIG. Most nations schedule bolandiol under HS 29061900 and SITC 51231.

As of Q4 2014, BOLANDIOL remains the US FDA Preferred Term for this commodity. SMILES: CCC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4OC(=O)CC)C.

UNSPSC 51182020 Bolandiol, a Commodity code, covers active pharmaceutical ingredients and finished pharmaceutical products supplied through cooperative purchasing agreements to state and local government healthcare facilities. State and local buyers under this code procure generic multi-source pharmaceuticals and over-the-counter products for distribution across participating agencies' medical and clinical operations, with supply routed through established pharmaceutical wholesalers operating chargeback systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent issuing body, extending purchasing access across participating state and local entities including Oregon. Vendors must meet stringent regulatory and operational requirements: cGMP and DSCSA compliance, NDC/SKU/UPC specification capability, EDI integration, maintenance of contractual relationships with authorized wholesalers, and comprehensive insurance coverage including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. Products must be available in the marketplace by the May 15, 2026 effective date with minimum six-month shelf life and one-year expiration dating from manufacture.

MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, represents the primary recent opportunity under this code. The solicitation seeks multiple awards across authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with pricing evaluated 75 percent on competitiveness, 10 percent on fixed pricing for contract term, 5 percent on administrative fee data format compliance, and 5 percent each on EDI capability and willingness to accept the 3 percent administrative fee. Contract term runs two years for new responders with optional MMCAP extensions, or alignment with incumbent agreement expiration through June 30, 2028. Performance violations incur penalties ranging from $200 to $1,500 per incident. No specific set-aside restrictions or dollar values were disclosed in available documentation.